Skip to main content
Clinical Trials/NCT00899405
NCT00899405
Recruiting
Not Applicable

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

University of California, Davis1 site in 1 country800 target enrollmentStarted: May 2005Last updated:
ConditionsLung Cancer

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
800
Locations
1
Primary Endpoint
Mutational status of the EGFR pathway

Overview

Brief Summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Detailed Description

OBJECTIVES:

  • Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
  • Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mutational status of the EGFR pathway

Time Frame: up to 1 year

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials